Home LiteratureArticle Details
PMID: 7821921 Published · ppublish English Journal Article Research Support, U.S. Gov't, P.H.S.

Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer.

Human pathology ·Vol. 26 ·No. 1 ·1995-01-00 ·Pages 86-91

Brown LF, Berse B, Jackman RW, Tognazzi K, Guidi AJ, Dvorak HF, Senger DR, Connolly JL, Schnitt SJ

Abstract

Solid tumors must induce a vascular stroma to grow beyond a minimal size, and the intensity of the angiogenic response has been correlated with prognosis in breast cancer patients. Vascular permeability factor (VPF), also known as vascular endothelial growth factor (VEGF), is a secreted protein that has been implicated in tumor-associated angiogenesis. Vascular permeability factor directly stimulates endothelial cell growth and also increases microvascular permeability, leading to the extravasation of plasma proteins, which alter the extracellular matrix in a manner that promotes angiogenesis. To determine whether VPF has a role in breast cancer, we used in situ hybridization to study VPF mRNA expression in normal breast tissue (13 specimens), comedo-type ductal carcinoma in situ (DCIS) (four specimens), infiltrating ductal carcinoma (12 specimens), infiltrating lobular carcinoma (two specimens), metastatic ductal carcinoma (three specimens) and metastatic lobular carcinoma (one specimen). Vascular permeability factor mRNA was expressed at a low level by normal duct epithelium but was expressed at high levels in tumor cells in all cases of comedo-type DCIS, infiltrating ductal carcinoma, and metastatic ductal carcinoma. In contrast, VPF mRNA was not expressed at high levels in infiltrating lobular carcinoma. We also used in situ hybridization to study the expression of two recently described endothelial cell surface VPF receptors, flt-1 and kdr. Vascular permeability factor receptor mRNA was strongly expressed in endothelial cells of small vessels adjacent to malignant tumor cells in DCIS, infiltrating ductal carcinoma, and metastatic ductal carcinoma. In contrast, no definite labeling for receptor mRNA was detected in infiltrating lobular carcinoma or nonmalignant breast tissue. The intense expression of VPF mRNA by breast carcinoma cells and of VPF receptor mRNA by endothelial cells of adjacent small blood vessels provides strong evidence linking VPF expression to the angiogenesis associated with comedo-type DCIS, infiltrating ductal, and metastatic ductal breast carcinoma.

MeSH Terms
Breast Neoplasms/metabolism Carcinoma/metabolism Carcinoma in Situ/metabolism Carcinoma, Ductal, Breast/metabolism Endothelial Growth Factors/genetics,metabolism Female Humans In Situ Hybridization Lymphokines/genetics,metabolism RNA, Messenger/metabolism Receptor Protein-Tyrosine Kinases/genetics,metabolism Receptors, Growth Factor/genetics,metabolism Receptors, Vascular Endothelial Growth Factor Vascular Endothelial Growth Factor A Vascular Endothelial Growth Factors
Chemicals
Endothelial Growth Factors Lymphokines RNA, Messenger Receptors, Growth Factor Vascular Endothelial Growth Factor A Vascular Endothelial Growth Factors Receptor Protein-Tyrosine Kinases Receptors, Vascular Endothelial Growth Factor
Authors & Affiliations
9 authors, click to expand affiliations / ORCID
Brown L F
Department of Pathology, Beth Israel Hospital, Boston, MA 02215.
Berse B
Jackman R W
Tognazzi K
Guidi A J
Dvorak H F
Senger D R
Connolly J L
Schnitt S J
Article Info
Journal
Human pathology
Abbr.
Hum Pathol
ISSN
0046-8177
Published
1995-01-00
Pages
86-91
Language
English
Region
United States
NLM ID
9421547
Subset
IM
Grants
NCI NIH HHS · CA43967 · United States
NCI NIH HHS · CA50453 · United States
NCI NIH HHS · CA58845 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com